目的:比较TX和TC新辅助化疗Ⅱ、Ⅲ期乳腺癌患者的近期疗效和毒副反应。方法:将47例Ⅱ、Ⅲ期乳腺癌患者随机分为两组，TX组20例接受TX（多西他赛+卡培他滨）方案和TC组27例接受TC（多西他赛+卡铂）方案化疗，21d为1个周期，两组患者均完成了4个周期的化疗，观察和比较4个周期新辅助化疗后两组的近期疗效和毒副反应。结果: TX组和TC组的总有效率分别为55.0%（11/20）和66.7%（18/27），两组比较差异无统计学意义（P=0.250）。 两组患者主要不良反应均为贫血、中性粒细胞和血小板减少、脱发、恶心及呕吐、肝功能异常和疲劳，两组比较差异无统计学意义（P>0.05）。但TX组患者出现手-足综合征、皮肤色素沉着、口腔黏膜炎和指甲变黑或脱落，在TC组并未出现。结论:TC与TX的4个周期新辅助化疗Ⅱ、Ⅲ期乳腺癌患者近期疗效相当，不良反应相似，但TX方案手-足综合征和全身色素沉着常见。
关键词：乳腺癌 新辅助化疗 临床疗效 毒副反应
Abstract Objective:To compare the efficacy and toxicity of TX and TC as neoadjuvant chemotherapy(NAC) for the patients with stage II-III breast cancer. Methods: 47 patients with Stage II and III breast cancer were randomly assigned to two groups . 20 patients in the TX group were given the chemotherapy of docetaxel and capecitabine, 27 patients in the TC group were given the chemotherapy of docetaxel and carboplatin. A treatment course lasted for 21 days, and both groups received 4 cycles of chemotherapy, we evaluate the efficacy and toxicity after 4 cycles program NAC. Results: Overall response rates in groups TX and TC were 55.0%(11/20) and 66.7%(18/27), respectively. no significant difference(p=0.250). The main toxic reactions in two groups were anemia, neutropenia, thrombocytopenia, alopecia, nausea, vomiting, liver dysfunction and asthenia, with no significant difference(P>0.05). But the TX group patients suffered from hand-foot syndrome, skin pigmentation, oral mucositis, nails black or fall off while TC group patients didn’t. Conclusion : The short-term efficacy of the 4 cycles TX and TC regimens as neoadjuvant chemotherapy for the patients with stage II-III breast cancer is similar with better efficacy. the side effect of two regimens are also similar, but hand-foot syndrome and skin pigmentation often occur in TX regimens.
Key words: breast cancer; neoadjuvant chemotherapy; clinical curative effect; adverse reaction;
引用本文 / How to Cite This Article
孔震.TX和TC新辅助化疗Ⅱ、Ⅲ期乳腺癌患者的疗效比较[J]. 国际精神病学杂志, , (): -